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Hematologic malignancies provide a suit-
able testing environment for cell-based
immunotherapies, which were pioneered
by the development of allogeneic hema-
topoietic stem cell transplant. All types
of cell-based therapies, from donor
lymphocyte infusion to dendritic cell
vaccines, and adoptive transfer of tumor-
specific cytotoxic T cells and natural killer
cells, have been clinically translated for
hematologicmalignancies. The recent suc-
cessofchimericantigen receptor–modified
T lymphocytes in B-cell malignancies
has stimulated the development of this
approach toward other hematologic tu-
mors. Similarly, the remarkable activity of
checkpoint inhibitors as single agents
has created enthusiasm for potential
combinations with other cell-based im-
mune therapies. However, tumor cells
continuously develop various strate-
gies to evade their immune-mediated
elimination. Meanwhile, the recruitment
of immunosuppressive cells and the
release of inhibitory factors contribute
to the development of a tumor microen-
vironment that hampers the initiation of
effective immune responses or blocks
the functions of immune effector cells.
Understanding how tumor cells escape
from immune attack and favor immuno-
suppression is essential for the improve-
ment of immune cell–based therapies
and the development of rational combina-
tion approaches. (Blood. 2016;127(26):
3350-3359)
Introduction
Combinational therapy, including chemotherapy, hematopoietic stem
cell transplant (HSCT), small molecules, immunomodulatory drugs,
andmonoclonal antibodies, can produce long-term remission or cure in
different hematologicmalignancies. In the continuous effort to develop
new therapeutic agents, cellular-based immunotherapies are gaining
increasing clinical relevance for hematologic malignancies. The
journey of cellular-based immunotherapy stems from the curative
effects of allogeneic HSCT, in which the donor’s immune cells
significantly contribute to the elimination of host tumor cells in
leukemia, lymphoma, and multiple myeloma.1-3 The graft-versus-
tumor effect after allogeneic HSCT, however, is frequently associated
with the occurrence of graft-versus-host disease, calling for more
effective and precise cell-based therapies.
Considering the variety and complexity of cellular interactions and
molecular pathways involved not only in promoting effective immune
responses, but also in blocking autoreactivity and excessive inflam-
mation, multiple cell-based approaches have been implemented
to educate immune responses against tumor cells, while preventing
toxicity. Dendritic cell (DC)-based vaccines and adoptive transfer of
cell subsets, such as cytotoxic T cells or natural killer cells (NKs),
have been used in clinical trials to prevent or treat relapse in both the
autologous and allogeneic clinical settings.4-6 More recently, immune
cell engineering and, in particular, the adoptive transfer of T cells that
express a chimeric antigen receptor (CAR) specific for the CD19
antigen have demonstrated remarkable antileukemia activity.7,8
Because of genomic instability and the effects of cancer immune
editing (reviewed elsewhere9,10), tumors develop multiple paths to
ultimately escape immune recognition and destruction. In this review
article, we only describe the tumor-associated escape mechanisms that
hamper immune responses in the context of hematologicmalignancies.
In parallel, we also reviewhow immune cell–based therapies have been
developed to overcome immune inhibition and the potential contribu-
tion of combinatorial treatment of therapeutic success.
Tumor-associated DC dysfunction
DCs are heterogeneous bone marrow–derived immune cells that play
an essential physiological role in the uptake and processing of antigens.
Upon antigen processing and exposure to danger/stress signals, such as
pathogen-associated molecular patterns, damage-associated molecular
patterns (DAMPs), or inflammatory mediators, DCs differentiate into
mature cells that express costimulatory molecules (CD80, CD86,
or CD40) and secrete chemokines and cytokines critical for priming
T- and B-cell responses.11
In cancer patients, DCs can engulf altered self-antigens or
neoantigens from tumor cells undergoing apoptosis due to hypoxia
or nutrient deprivation,12 and in the presence of danger signals, such
as DAMP-related signals, they can promote antitumor immune
responses.13,14 However, tumor cells and other components of the
tumor microenvironment cause quantitative and qualitative defects
in the DCs of patients with hematologic malignacies.15-18 Soluble
factors such as interleukin-6 (IL-6), macrophage colony-stimulating
factor, or vascular endothelial growth factor (VEGF) can block DC
differentiation from bone marrow precursors or promote the
differentiation of tolerogenic DCs or other immunosuppressive cell
subsets.19,20 Tumor-associated factors such as cyclooxygenase-2
(COX-2)/prostaglandin E2 (PGE2), transforming growth factor-b
(TGF-b), and VEGF can also halt DC functions, including
phagocytosis, antigen processing, the expression of costimulatory
molecules and activation markers, and the secretion of IL-12, which
all lead to T-cell tolerance21,22 (Figure 1).
Overcoming tumor-associated DC
dysfunction
Although dysfunctional in vivo in cancer patients, functionally potent
DCs can be generated ex vivo from different sources, including
circulating CD141 monocytes or CD341 hematopoietic stem cells.
Robust evidence showing that DCs can elicit tumor-specific T cells
in vitro has powered the clinical translation of DC-based vaccines.23
DCs generated ex vivo and exposed to agents like PGE2, pathogen
recognition receptor agonists, and tumor necrosis factor-a (TNF-a) can
indeed regain and retain functionality upon inoculation in patients and
thus potentially take over dysfunctional resident DCs.24 Several
approaches have been used to load ex vivo tumor-associated antigens
into DCs. The range of loaded antigens has been broadened by using
tumor cell lysates, tumor apoptotic bodies or exosomes, tumor-derived
messenger RNA libraries, or tumor-DC fusion; conversely, the range
of loaded antigens has been restricted to specific tumor-associated
proteins or even epitopes, such as the idiotype portion of B-cell
immunoglobulins, NY-ESO-1 or WT1.25-28 Clinical trials using
DC-based vaccines have been conducted in patients with lymphoma,
myeloma, and leukemia, showing safety, elicitation of immune responses,
and promising objective responses in some studies28 but not in
others.25,27,29 Although improvement in overall survival granted US
Food and Drug Administration approval for a DC-based vaccine for
prostate cancer (sipuleucel-T),30 currently, no DC-based vaccine is
approved for hematologic malignancies. Although the overall low
response rate of the DC-based approach in cancer patients is likely to
be multifactorial, one of the most plausible barriers remaining is the
eventual blunting of immune responses by the inoculated DCs
promoted through the same tumor-associated inhibitory mecha-
nisms that hamper the functions of endogenous DCs. Ex vivo DC
engineering by knocking down suppressor of cytokine signaling 131
to enhance antigen presentation, or by inserting an inducible CD40
receptor32 to pharmacologically stimulate the CD40/CD40L pathway,
has been developed to increase the in vivo potency of DCs, and some of
these approaches have reached clinical translation. The administration of
DC-based vaccines in the posttransplant setting offers the advantages
of significantly reducing the tumor burden and related im-
munosuppressive cellular and soluble factors, and of priming T cells
that reemerge after cell ablation.33 Finally, combinations of DC-based
vaccineswith immunomodulatory agents such as lenalidomide or anti-
programmeddeath1 (PD-1)andanti-programmeddeath ligand1(PD-L1)
antibodies are in clinical development andmay reinvigorate thefield of
vaccine strategies for hematologic malignancies34 (Table 1).
Defective tumor antigen presentation
and costimulation
When effective antitumor T-cell responses are elicited by functional
DCs, the recognition and destruction of malignant cells by effector
CD81T cells occurs only after peptides derived from tumor-associated











Figure 1. Tumor-associated DC dysfunction. Tumor 
cells and the tumor microenvironment can cause 
quantitative and qualitative defects in DCs, which are 
mostly mediated by soluble factors. CTL, cytotoxic T 
lymphocyte; M-CSF, macrophage colony-stimulating 
factor; MHC I, major histocompatibility complex class I; 
TCR, T-cell receptor.
downregulation or loss of MHC molecules due to mutations or
deletions of HLA loci has been extensively described in hemato-
logic malignancies. Loss of MHC class I expression, 75% of which
relates to the aberrant expression of b2-microglobulin, occurs in
over 50% of diffuse large B-cell lymphomas.35,36 Similarly, exome
sequencing has confirmed thatb2-microglobulin is themost frequently
mutated gene inHodgkin lymphoma.37 Loss ofMHCclass Imolecules
can cause tumor escape from T cells targeting the NY-ESO-1 antigen,
whereas loss of the HLA haplotype can occur in leukemic cells after
haploidentical HSCT.38,39 Genes involved in the antigen processing/
presentation machinery, such as the transporters associated with
antigen processing 1/2, can also be downregulated in lymphomas.40
Finally, mutations, deletions, and rearrangements of the class II
MHC transactivator mediate the downregulation of MHC class II
molecules, therefore evading CD41 T-cell recognition.41 In spite of
the MHC downregulation and defects in antigen presentation, in
patients with Epstein-Barr virus (EBV)-related lymphomas signif-
icant clinical responses have been achieved after adoptive transfer of
virus-specific cytotoxic T cells.42 In addition, some responses have
been obtained in patients with myeloma and acute myeloid leukemia
after adoptive transfer of T cells expressing high-affinity TCRs
for HLA-A2–restricted NY-ESO-1 or HLA-A2–restricted WT1
peptides.43,44 These data may reflect either the heterogeneity of
tumor cell populations or the effect of epigenetic mechanism(s)
causing the dynamic regulation of class I expression by tumor cells
in vivo when deletions or mutations are not the primary cause of
dysfunctional antigen processing.
In order to achieve an optimal level of activation, T cells require
signaling from costimulatory molecules. One of the most well-
characterized costimulatory pathways links the CD28 molecule expressed
by T cells to the CD80/86 molecules expressed by antigen-presenting
cells. The CD28-CD80/CD86 interaction facilitates the formation of the
immunological synapse around the TCR-MHC complex and enhances
TCR signaling and T-cell activation.45 TCR binding in the absence of
costimulation drives T cells to anergy, a well-described event for
hematologic malignancies, which frequently lack the expression of
CD80/CD86 molecules46 (Figure 2).
Prevailing defective antigen presentation and
costimulation processes of tumors
T cells genetically modified to express CARs provide a compelling
immune cell–based strategy that overcomes both defective antigen
presentation and costimulation by tumor cells. CARs are fusion
proteins in which a single-chain variable fragment, derived from a
monoclonal antibody recognizing a cell surface antigen, is coupled
with a signaling molecule (CD3z or FcgRI) that activates signaling
downstream from the TCR. Similar to antibodies, the antigen
recognition of CARs is independent ofMHC restriction and overcomes
the tumor’s immune ignorance caused by downmodulation of HLA
molecules.47 In addition, CARs can be further engineered in tandem to
express costimulatory moieties, such as CD28, 4-1BB, or OX40, to
promote T-cell costimulation upon engagement of the antigen expressed
by tumor cells.48-50 Clinical trials in patients with B-cell lymphoid
malignancies receiving CAR-redirected T cells targeting CD19 have
now convincingly demonstrated that CAR-mediated T-cell costimula-
tion occurs in vivo51 and promotes over 70% response rate in patients
with acute lymphoblastic leukemia.8,52 Encouraging results have also
been obtained in patients with chronic lymphocytic leukemia53
and lymphomas.54
Table 1. Tumor immune evasion strategies
Defects Immune cell-based therapies
Combinations with immune
cell–based therapies
Tumor-associated DC dysfunction Reduced DC numbers DCs generated ex vivo Posttransplant setting
Immature or tolerogeneic DCs Engineered DCs Immunomodulatory drugs
Treg inhibition
Checkpoint inhibitors
Tumor defective antigen presentation and
costimulation
Impaired antigen processing and
presentation
T cells, NKs, and NKTs expressing CARs Pharmacologic modulation of the
epigenetic profile
MHC downregulation and HLA loss Allogeneic NKs
Lack of costimulatory molecules TCR-redirected T cells
EBV-specific T cells
Tumor resistance to cytolysis and
induction of immune exhaustion
Loss of Fas/TRAIL-R T cells, NKs, and NKTs expressing CARs BCL-2 inhibitors








Increased Tregs, TAMs, and MDSCs DCs or engineered ex vivo expanded Posttransplant setting
T cells, NKs, and NKTs expressing CARs Lymphodepletion
Allogeneic NKs Selective elimination or reprogramming of
Tregs, TAMs, and MDSCs
TCR-redirected T cells
EBV-specific T cells
Tumor-associated soluble factors Immunosuppressive cytokines (IL10, IL6,
TGF-b, VEGF)










IDO Adenosine receptor inhibitors
Lossor downregulation ofHLAclass Imolecules can be potentially
restored by the administration of drugs that modulate the epigenetic
profile of tumor cells, including mediators of histone acetylation/
deacetylation, histone methylation, and DNA methylation.40 Never-
theless, loss of HLA class I molecules renders tumor cells susceptible
to NK-mediated cytotoxicity because of the missing interactions
between MHC molecules and inhibitory NK receptors. However, NK
dysfunctions are frequently found in hematologic malignancies. NKs
isolated from patients with acute myeloid leukemia or multiple
myeloma show aberrant increases in inhibitory receptors vs activation
receptors, causing inhibition of NK cytotoxic activity.55 Overexpres-
sion of CD94/NKG2A inhibitory receptors on NKs is also associated
with increased incidence of relapse after allogeneic HSCT.56 Finally,
tumor cells can shed MHC class I chain-related genes A and B, which
are ligands of the activation receptor NKG2D, to induce chronic
stimulation and cell anergy.57 In an effort to revert some of the NK
dysfunctions, NKs have been expanded ex vivo and adoptively
transferred in patients with leukemia and multiple myeloma. While
showing effective cytotoxic activity ex vivo, few objective responses
have been reported after infusion of autologous NKs. In sharp contrast,
NKs adoptively transferred in the context of allogeneicHSCTappear to
persist and promote complete responses in patients with acute myeloid
leukemia.58 Engineering of NKs with CARs may further extend the
clinical relevance of NK-cell–based immunotherapy by broadening
their target spectrum.59
NK T cells (NKTs) are another T-cell subset that has therapeutic
potential for hematologic malignancies. NKTs recognize exogenous
and endogenous glycolipids presented by the nonclassic MHC-like
molecule CD1d.60 NKTs, which are interconnected with DCs,
macrophages, CD81 T cells, and NKs via the release of Th1 and Th2
cytokines, have a recognized role in the host defenses between innate
and adaptive immunity. Type I NKTs (also called invariant NKTs)
express the invariant TCRa-chain, are readily detectable by
a-galactosylceramide–loaded CD1d tetramers, and can target tumor
cells of lymphoid or myeloid lineage.61 Increasing interest is
directed to the potential for invariant NKTs to be expanded ex vivo
and engineered to express CARs, to add other antigen specificities
while maintaining their native property of targeting the glycolipid/
CD1d.62 Because of their lack of alloreactivity, invariant NKTs
also have significant potential in the context of allogeneic HSCT62
(Table 1).
Tumor resistance to cytolysis and induction
of immune exhaustion
T cells, NKs, and NKTs induce tumor cell death through perforin-
granzyme B–mediated tumor lysis and/or Fas-FasL/TNF-related
apoptosis-inducing ligand (TRAIL)-mediated apoptosis. However,
tumor cells can either develop intrinsic resistance to immune-mediated
lysis or directly promote immune cell exhaustion. Convincing evidence
indicates that cancer-initiating cells in hematologic malignancies are
inherently resilient to many chemotherapy drugs and irradiation not
only because of the expression of drug efflux proteins and relatively
quiescent status within the stem cell niche,63 but also because tumor
cells can escape immune elimination by developing resistance to
perforin-mediated lysis and expressing high levels of the serpin
proteinase inhibitor 9 to hijack granzymeB.64Downregulation of death
receptors, overexpression of antiapoptotic proteins (eg, cellular Fas-
associated death domain–like IL-1b-converting enzyme–inhibitory
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Figure 2. Tumor-defective antigen presentation 
and costimulation, resistance to cytolysis, and 
induction of immune exhaustion. Tumor cells can 
escape immune recognition by downregulating MHC 
class I molecules and costimulatory molecules and by 
developing defective antigen processing. Tumor cells 
can also resist the cytolytic effects of immune cells by 
overexpressing antiapoptotic molecules or inhibitory 
ligands. PD-L1 expression by tumor cells causes T-cell 
exhaustion. APM, antigen-presenting machinery.
FasL, and release of decoy death receptors are other well-described
means for tumor cells to blockor prevent their engagementwith effector
immune cells.65,66 Constitutive or interferon-g–induced expression of
PD-L1 by tumor cells is emerging as a compelling tumor-associated
escapemechanism.67 PD-1–expressing T cells at the tumor site receive
suppressive and/or exhaustive signals upon engagement with tumor-
expressing PD-L1.68 This effect clearly plays a critical role in the
immune escape of hematologic malignancies.69 NKs are also highly
sensitive to the PD-1/PD-L1 inhibitory pathway as shown in multiple
myeloma.70 Fewer studies are available for NKTs, but preclinical
models suggest that these cells are not immune from PD-L1 sup-
pression. Interfering with the PD-1/PD-L1 interaction using PD-1– or
PD-L1–blocking antibodies has resulted in remarkable clinical re-
sponses as a single treatment in patients with Hodgkin lymphoma, and
many studies in leukemia, lymphoma, and multiple myeloma are
currently ongoing69 (Figure 2).
Counteracting tumor resistance to cytolysis
and induction of immune exhaustion
Although the intrinsic cytolytic properties of effector immune cells
cannot realistically be manipulated in vivo or ex vivo, efforts can be
envisioned for combining adoptive transfer of tumor-specific T cells or
NKs with small molecules targeting antiapoptotic pathways in tumor
cells. Recombinant TRAIL and monoclonal antibodies specific for
death receptors have been used to activate the extrinsic apoptosis
pathway in tumor cells.71 Bcl-2 inhibitors, histone deacetylase
inhibitors, and proteasome inhibitors, which upregulate death receptors
and proapoptotic proteins in tumor cells, are fueling studies for
combination treatment with immune cell–based therapy.72 However,
the potential toxicity of these drugs on immune cells must be carefully
considered. For example, small molecules interfering with the Bcl-2
pathway may not discriminate between tumor and T cells and cause
detrimental effects to the latter because Bcl-2 is involved in the
activation and maturation of T lymphocytes after antigen presenta-
tion.73 By contrast, the combination of immune cell–based therapies
with anti-PD-1– or anti-PD-L1–blocking antibodies is expected
to greatly enhance the efficacy of adoptive cell-based therapies.
Blocking PD-1/PD-L1 can indeed promote not only the emergence
of endogenous T cells that target neoantigens expressed by tumor
cells, but can also potentially unleash adoptively transferred immune
cells, which would be similarly susceptible to PD-L1–mediated
blocking at the tumor site (Table 1).
Tumor-associated immune-suppressive cells
Immune cells in the bone marrow and lymphoid organs are located in
specific niches and contribute in regulating normal hematopoiesis.
However, stem cell niches also play key roles in the development of
malignancies and in maintaining cancer-initiating cells.63 Tumor cells
in the bone marrow and lymph nodes are also often surrounded by
different types of nonmalignant cells such as regulatory T cells (Tregs),
tumor-associated macrophages (TAMs), and myeloid-derived sup-
pressor cells (MDSCs) that create a functionally inhibitory microen-
vironment, through direct cell-to-cell contact with immune cells or
through soluble factors. Although increased frequency of Tregs
is widely appreciated in hematologic malignancies,74-77 MDSCs and
TAMs only recently became objects of interest on the basis of
compelling gene expression profiling data.41,78-82
CD41CD251Foxp31 Tregs suppress effector T cells mainly
through cell-contact inhibition, secretion of inhibitory cytokines
(TGF-b, IL-4, and IL-10) and competition for IL-2 consumption.83,84
NKs are also inhibited in their cytolytic function and expression of
activationmarkers byTregs viaTGF-b.85 TAMs,which aremonocytes
and macrophages infiltrating the tumor, are frequently defined as M1
and M2 macrophages based on the type of activation signals they
receive. Although this categorization is subject to constant discussion
and revision,M2macrophages are generally considered to favor tumor
growth, whereas M1 macrophages support immune cell functions
through secretion of proinflammatory molecules.86,87 M2 macro-
phages can directly inhibit T- and NK-cell function and survival
by expressing PD-L188 or the nonclassical HLA-Gmolecule89 and
by secreting the inhibitory cytokines IL-10 and TGF-b.90 Through
the secretion of CCL22, TAMs further contribute to the recruitment
of immunosuppressive Tregs.91 MDSCs consist of a heterogeneous
group of cells of myeloid origin, commonly characterized in humans
as polymorphonuclear MDSCs (CD11b1CD142CD151 or CD11b1
CD142CD66b1) andmonocyticMDSCs(CD11b1CD141HLA-DRlow),
although the former are the most abundant in cancer patients.92,93
MDSCs are a major source of T-cell inhibitory cytokines such as
IL-10 and TGF-b.92,94 They also induce reactive oxygen species to
create oxidative stress and stimulate Tregs, which further exacer-
bates the immunosuppressive properties of the tumor microenviron-




Depletion of inhibitory Tregs, TAMs, and MDSCs is likely critical to
enhance the success of vaccine strategies and adoptive transfer of
effector cells in hematologic malignancies. In this regard, DC-based
vaccines administered after HSCT and infusion of effector cells after
myeloid/lymphodepleting regimens are the most simplistic means to
achieve this goal. When combined with the adoptive transfer of
immunecells, lymphodepletion also reduces the invivo competition for
the homeostatic cytokines IL-7 and IL-15, which are consequently
available to the transferred T cells.96 Still, agents capable ofmodulating
the inhibitory cell components of the tumor microenvironment more
precisely and with less toxicity are in high demand. The administration
of low doses of chemotherapy that causeminimal deleterious effects on
T cells and NKs, such as metronomic cyclophosphamide regimens,
gemcitabine and trabectedin, can be envisioned to sustain long-term
depletion of Tregs, MDSCs, and TAMs.97-99
Selective depletion of Tregs has also been reported using the
IL-2–diphtheria toxin conjugate (denileukin diftitox [Ontak]), which
triggers Treg apoptosis through irreversible inhibition of protein
synthesis, but clinical benefits remain limited due to the high
immunogenicity of themolecule.58,100 Several other proteins, including
Toll-like receptors, CTLA-4, TNF superfamily receptor OX40, and
glucocorticoid-induced TNF receptor directly or indirectly control Treg
functions. Based on these discoveries, various agents, such as CpG,
Toll-like receptor signalingmodulators, and blocking (anti-CTLA-4) or
agonistic (anti-OX40 and anti-glucocorticoid-induced TNF receptor)
antibodies, have been developed to suppress the activity of Tregs.101-103
TAMs can be targeted by preventing their recruitment/activation at
the tumor site or changing their function by taking advantage of their
plasticity once they have been recruited within the tumor. Inhibition
of the CCL2/CCR2 axis prevents the recruitment of monocytes/
macrophages.104 Similarly, macrophages can be inhibited by blocking
the CSF1/CSF1R axis or reprogrammed by activating the CD40
pathway.105,106 Finally, as M2macrophages express CD1d molecules,
either constitutively or following exposure to retinoids, they are a
potential target for NKTs.107
MDSCs can likewise be selectively inactivated or reprogrammed
in vivo. Inhibitors of COX-2, reactive oxygen species, and nitric
oxide synthase 2 can block the immunosuppressive functions of
MDSCs,108,109 whereas vitamins and derivatives (vitamin A, D3, E,
and all-trans retinoic acid) can reprogram MDSCs to nonsuppressive
myeloid cells.110,111 Therefore, combinations of strategies that
selectively counteract Tregs, TAMs, and MDSCs with DC-based
vaccines or adoptive transfer of immune cells are expected to
enhance efficacy without significantly increasing toxicity (Table 1).
Tumor-associated soluble factors
Several soluble factors produced by hematologic malignant cells or
stromal cells within the tumor environment significantly contribute to
impair the survival and functions of effector cells and preserve the
immunosuppressive environment. Cytokines such as IL-10, TGF-b,
andVEGF are associatedwith disease progression and poor survival in
several hematologic malignancies. Tregs, MDSCs, and M2 macro-
phages are common sources of IL-10, which causes downregulation of
MHC molecules on DCs and tumor cells and directly suppresses Th1
cytokine release by T cells.112 Both soluble and membrane-bound
TGF-b can be detected in hematologic malignancies, leading to
prolonged inhibition of T-cell proliferation, activation, and cytokine
secretion.113 Moreover, both IL-10 and TGF-b contribute to the self-
maintenance of the immunosuppressive environment by promoting the
generation of induced Tregs.114 Finally, VEGF, in addition to its
proangiogenic effects, impairs DC maturation and directly inhibits
T-cell proliferation and cytotoxic activity.115 Besides cytokines, chemo-
kines primarily contribute to the recruitment of inhibitory immune cells.
For instance, Reed-Sternberg cells are well characterized for their
production of CCL22, CCL17/TARC and CCL5/RANTES, which are
critical in the recruitment of Tregs, Th2 cells, monocytes, and mast
cells116 (Figure 3).
Evading tumor-associated soluble factors
Although the elimination or reprogramming of Tregs, TAMs, and
MDSCs per se is anticipated to remove the inhibitory effects of soluble
factors produced by these cells, specific countermeasures have been
implemented through the direct genetic engineering of ex vivo–
expanded immune cells. The inhibitory effects of TGF-b can be
blocked by expressing a dominant-negative TGF-b receptor II in
tumor-specific T cells, and clinical trials in lymphoma and melanoma
patients are ongoing to assess the impact of this modification.117 T-cell
costimulation through CARs, IL-15 delivery at the tumor site, and
modification of the cytokine/cytokine receptor axis in effector cells can
circumvent the inhibition of T-cell proliferation.118-121 Alternatively,
the local production of cytokines, such as IL-12, can be helpful in
reverting the inhibitory tumor environment, even without directly
promoting T-cell proliferation.122,123 Finally, transferred tumor-
specific T cells can be engineered to tune chemokine-chemokine
receptor pathways and thus favor T-cell recruitment at the tumor site.124
How to prioritize these multiple actions remains largely unknown, and
it is anticipated that combinations of multiple factors will prove critical
to optimize antitumor effects.125 However, although optimization of
effector immune cell trafficking at the tumor site is likely a priority for
solid tumors, in hematologic malignancies, engineering T cells to
overcome the inhibitory effects of TGF-b could be highly advanta-
geous because TGF-b is almost invariably present in all myeloid
and lymphoid tumors (Table 1). In the near future, the development of

























Figure 3. Tumor-associated immune-suppressive 
cells, soluble factors, and immune cell metabo-
lism. Tumor cells are surrounded by several cell 
subsets including Tregs, TAMs, and MDSCs, which 
hamper the function of cytotoxic T cells and NK cells. 
Chemokines play a critical role in recruiting inhibitory 
cells, whereas soluble factors such as TGF-b, nutrient 
deprivation, and hypoxia impair the proliferation and 
function of effector cells.
T cells to become simultaneously resistant to multiple inhibiting
factors.126
Tumor-altered immune cell metabolism
The metabolic activity and alteration in the metabolic program of
immune cells, and in particular inT cells andNKs, is gaining significant
attention in thefieldof immunecell-based immunotherapies.The tumor
microenvironment in both solid and hematologic malignancies
significantly shapes the metabolic program of the immune cells,
leading to their dysfunction or death at the tumor site. The transition
fromnaive to effectorT cells determines a drastic switch fromoxidative
phosphorylation to glycolysis as provision to the high demand of
protein synthesis for cell growth and effector functions.127 In addition,
in rapidly growing tumors, the development of blood vessels is
generally overturned by tumor cell outgrowth leading to a limited
supply of nutrients. Glucose and amino acids play an important role
in T-cell metabolism and the deprivation of these nutrients directly
correlates with impaired immune responses. Glucose deprivation
causes severe impairment of the proliferation and effector functions
of T cells.128 Similarly, tumor cells, MDSCs and stromal cells can
sequester cysteine and express the arginase-1 and indoleamine-pyrrole
2,3-dioxygenase (IDO) enzymes, whose main functions are to deprive
arginine and tryptophan from the environment, while causing the
accumulation of immunosuppressive metabolites that arrest T-cell
proliferation and induce apoptosis.129-131 The suboptimal vasculariza-
tion of the tumormicroenvironment, in addition to nutrient deprivation,
causes insufficient oxygen supply or hypoxia. Although more
prominent in solid tumors than hematologic malignancies, hypoxia
impairs T- and NK-cell proliferation, cytolytic activity, the expression
of activating receptors and cytokine secretion, which exacerbates the
immunosuppression.132 Hypoxic environments also favor the accu-
mulation of adenosine, which in turn can directly inhibit T-cell
responses upon bindingwith the adenosine A2A receptor expressed by
activated T cells133 (Figure 3).
Bypassing the tumor-altered immune
cell metabolism
Targeting the metabolism or metabolites of the tumor microenviron-
mentmay improve the clinical efficacy of cell immune-based therapies.
IDO has been implicated in affecting the function of CAR-redirected
T cells, and the combination of cell-based immune therapies with IDO
inhibitors such as 1-methyl-triptophan and INCB024360 may protect
these cells from IDO-mediated inhibition and promote T-cell survival,
proliferation, and function.134,135 Developing nontoxic A2A receptor
inhibitors, correcting the glucose metabolism of the tumor to reduce
its competition with effector immune cells, or reprogramming
T-cell metabolism to enhance their function in conditions of
glucosedeprivationare intriguingnewconcepts thatmayhave immediate
translational application136,137 (Table 1). Finally, a recent study of
multiple myeloma also showed that myeloma-infiltrating lymphocytes
may be imprinted to adapt to hypoxia, suggesting that a better
understanding of the mechanisms of adaptation may be helpful for
increasing the functionality of T cells in hypoxia.138
Conclusions and future prospective
Fueled by the unprecedented success of CAR-redirected T cells, cell-
based immunotherapy is a realistic and effective approach for the
treatment of acute lymphoblastic leukemia. Combinations of cellular
therapies with other treatment modalities are likely crucial for curing
other hematologic malignancies such as lymphomas, myeloma, and
chronic lymphocytic leukemia. However, when considering combina-
tion approaches, some degree of prioritization must be taken into
account. The current clinical experience suggests that host lymphode-
pletion before adoptive T-cell therapy is essential for ensuring adequate
expansion of infused cells and should be incorporated within clinical
protocols. Fludarabine and cyclophosphamide are frequently used
to achieve adequate host lymphodepletion.54 However, the develop-
ment of less toxic but equally effective regiments remains critical. The
remarkable clinical activity of checkpoint inhibitors urges their
combination with adoptively transferred CAR T cells or TCR-
modified T cells or cell-based vaccines. Another clear need is the rapid
clinical validation of drugs or antibodies that selectively block or
deplete Tregs,MDSCs, andmacrophages and their future combination
with cell immune-based therapies.
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in activatory and inhibitory natural killer (NK)
receptors may induce progression to multiple
myeloma: implications for tumor evasion of
T and NK cells. Hum Immunol. 2009;70(10):
854-857.
56. Nguyen S, Beziat V, Dhedin N, et al. HLA-E
upregulation on IFN-gamma-activated AML
blasts impairs CD94/NKG2A-dependent NK
cytolysis after haplo-mismatched hematopoietic
SCT. Bone Marrow Transplant. 2009;43(9):
693-699.
57. Salih HR, Antropius H, Gieseke F, et al.
Functional expression and release of ligands
for the activating immunoreceptor NKG2D in
leukemia. Blood. 2003;102(4):1389-1396.
58. Bachanova V, Cooley S, Defor TE, et al.
Clearance of acute myeloid leukemia by
haploidentical natural killer cells is improved
using IL-2 diphtheria toxin fusion protein. Blood.
2014;123(25):3855-3863.
59. Chu J, Deng Y, Benson DM, et al. CS1-specific
chimeric antigen receptor (CAR)-engineered
natural killer cells enhance in vitro and in vivo
antitumor activity against human multiple
myeloma. Leukemia. 2014;28(4):917-927.
60. Metelitsa LS. Anti-tumor potential of type-I
NKT cells against CD1d-positive and CD1d-
negative tumors in humans. Clin Immunol. 2011;
140(2):119-129.
61. Lepore M, de Lalla C, Gundimeda SR, et al. A
novel self-lipid antigen targets human T cells
against CD1c(1) leukemias. J Exp Med. 2014;
211(7):1363-1377.
62. Heczey A, Liu D, Tian G, et al. Invariant
NKT cells with chimeric antigen receptor provide
a novel platform for safe and effective cancer
immunotherapy. Blood. 2014;124(18):
2824-2833.
63. Schepers K, Campbell TB, Passegué E. Normal
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associated macrophages as a prognostic
parameter in multiple myeloma. Ann Hematol.
2013;92(5):669-677.
83. Sakaguchi S, Yamaguchi T, Nomura T, Ono M.
Regulatory T cells and immune tolerance. Cell.
2008;133(5):775-787.
84. Vignali DA, Collison LW, Workman CJ. How
regulatory T cells work. Nat Rev Immunol. 2008;
8(7):523-532.
85. Xu L, Tanaka S, Bonno M, et al. Cord blood CD4
(1)CD25(1) regulatory T cells fail to inhibit cord
blood NK cell functions due to insufficient
production and expression of TGF-beta1.
Cell Immunol. 2014;290(1):89-95.
86. Sica A, Mantovani A. Macrophage plasticity and
polarization: in vivo veritas. J Clin Invest. 2012;
122(3):787-795.
87. Noy R, Pollard JW. Tumor-associated
macrophages: from mechanisms to therapy
[published correction appears in Immunity. 2014;
41(5):866]. Immunity. 2014;41(1):49-61.
88. Duraiswamy J, Freeman GJ, Coukos G.
Therapeutic PD-1 pathway blockade augments
with other modalities of immunotherapy T-cell
function to prevent immune decline in ovarian
cancer. Cancer Res. 2013;73(23):6900-6912.
89. Posch PE, Borrego F, Brooks AG, Coligan JE.
HLA-E is the ligand for the natural killer cell
CD94/NKG2 receptors. J Biomed Sci. 1998;5(5):
321-331.
90. Pollard JW. Tumour-educated macrophages
promote tumour progression and metastasis. Nat
Rev Cancer. 2004;4(1):71-78.
91. Curiel TJ, Coukos G, Zou L, et al. Specific
recruitment of regulatory T cells in ovarian
carcinoma fosters immune privilege and predicts
reduced survival. Nat Med. 2004;10(9):942-949.
92. Marvel D, Gabrilovich DI. Myeloid-derived
suppressor cells in the tumor microenvironment:
expect the unexpected. J Clin Invest. 2015;
125(9):3356-3364.
93. Filipazzi P, Valenti R, Huber V, et al.
Identification of a new subset of myeloid
suppressor cells in peripheral blood of
melanoma patients with modulation by a
granulocyte-macrophage colony-stimulation
factor-based antitumor vaccine. J Clin Oncol.
2007;25(18):2546-2553.
94. Huang B, Pan PY, Li Q, et al. Gr-11CD1151
immature myeloid suppressor cells mediate the
development of tumor-induced T regulatory cells
and T-cell anergy in tumor-bearing host. Cancer
Res. 2006;66(2):1123-1131.
95. Liu C, Yu S, Kappes J, et al. Expansion of spleen
myeloid suppressor cells represses NK cell
cytotoxicity in tumor-bearing host. Blood. 2007;
109(10):4336-4342.
96. Dudley ME, Wunderlich JR, Yang JC, et al.
Adoptive cell transfer therapy following
non-myeloablative but lymphodepleting
chemotherapy for the treatment of patients with
refractory metastatic melanoma. J Clin Oncol.
2005;23(10):2346-2357.
97. Ghiringhelli F, Menard C, Puig PE, et al.
Metronomic cyclophosphamide regimen
selectively depletes CD41CD251 regulatory
T cells and restores T and NK effector functions
in end stage cancer patients. Cancer Immunol
Immunother. 2007;56(5):641-648.
98. Suzuki E, Kapoor V, Jassar AS, Kaiser LR,
Albelda SM. Gemcitabine selectively eliminates
splenic Gr-11/CD11b1 myeloid suppressor
cells in tumor-bearing animals and enhances
antitumor immune activity. Clin Cancer Res.
2005;11(18):6713-6721.
99. Germano G, Frapolli R, Belgiovine C, et al. Role
of macrophage targeting in the antitumor activity
of trabectedin. Cancer Cell. 2013;23(2):249-262.
100. Dannull J, Su Z, Rizzieri D, et al. Enhancement
of vaccine-mediated antitumor immunity in
cancer patients after depletion of regulatory
T cells. J Clin Invest. 2005;115(12):3623-3633.
101. Pasare C, Medzhitov R. Toll pathway-dependent
blockade of CD41CD251 T cell-mediated
suppression by dendritic cells. Science. 2003;
299(5609):1033-1036.
102. Callahan MK, Wolchok JD, Allison JP. Anti-
CTLA-4 antibody therapy: immune monitoring
during clinical development of a novel
immunotherapy. Semin Oncol. 2010;37(5):
473-484.
103. Ko K, Yamazaki S, Nakamura K, et al. Treatment
of advanced tumors with agonistic anti-GITR
mAb and its effects on tumor-infiltrating Foxp31
CD251CD41 regulatory T cells [published
correction appears in J Exp Med. 2012;209(2):
423]. J Exp Med. 2005;202(7):885-891.
104. Qian BZ, Li J, Zhang H, et al. CCL2 recruits
inflammatory monocytes to facilitate breast-
tumour metastasis. Nature. 2011;475(7355):
222-225.
105. Loberg RD, Ying C, Craig M, Yan L, Snyder LA,
Pienta KJ. CCL2 as an important mediator of
prostate cancer growth in vivo through the
regulation of macrophage infiltration. Neoplasia.
2007;9(7):556-562.
106. Lum HD, Buhtoiarov IN, Schmidt BE, et al.
In vivo CD40 ligation can induce T-cell-
independent antitumor effects that involve
macrophages. J Leukoc Biol. 2006;79(6):
1181-1192.
107. Metelitsa LS, Naidenko OV, Kant A, et al.
Human NKT cells mediate antitumor cytotoxicity
directly by recognizing target cell CD1d with
bound ligand or indirectly by producing IL-2 to
activate NK cells. J Immunol. 2001;167(6):
3114-3122.
108. Califano JA, Khan Z, Noonan KA, et al. Tadalafil
augments tumor specific immunity in patients
with head and neck squamous cell carcinoma.
Clin Cancer Res. 2015;21(1):30-38.
109. Nagaraj S, Youn JI, Weber H, et al. Anti-
inflammatory triterpenoid blocks immune
suppressive function of MDSCs and improves
immune response in cancer. Clin Cancer Res.
2010;16(6):1812-1823.
110. Mirza N, Fishman M, Fricke I, et al. All-trans-
retinoic acid improves differentiation of myeloid
cells and immune response in cancer patients.
Cancer Res. 2006;66(18):9299-9307.
111. Kusmartsev S, Cheng F, Yu B, et al. All-trans-
retinoic acid eliminates immature myeloid cells
from tumor-bearing mice and improves the effect
of vaccination. Cancer Res. 2003;63(15):
4441-4449.
112. Mocellin S, Marincola FM, Young HA.
Interleukin-10 and the immune response against
cancer: a counterpoint. J Leukoc Biol. 2005;
78(5):1043-1051.
113. Dong M, Blobe GC. Role of transforming growth
factor-beta in hematologic malignancies. Blood.
2006;107(12):4589-4596.
114. Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble
and membrane-bound TGF-b-mediated
regulation of intratumoral T cell differentiation
and function in B-cell non-Hodgkin lymphoma.
PLoS One. 2013;8(3):e59456.
115. Cirone M, Lucania G, Aleandri S, et al.
Suppression of dendritic cell differentiation
through cytokines released by primary effusion
lymphoma cells. Immunol Lett. 2008;120(1-2):
37-41.
116. van den Berg A, Visser L, Poppema S. High
expression of the CC chemokine TARC in Reed-
Sternberg cells. A possible explanation for the
characteristic T-cell infiltratein Hodgkin’s
lymphoma. Am J Pathol. 1999;154(6):
1685-1691.
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